Skye Bioscience's CEO Punit Dhillon discusses next generation CB1 inhibition for obesity, and flags how key data from competitor Novo coming this quarter could impact the class

blonca9
Aug 30, 2024
1 min read

He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better and more tolerable than previous generations. Plus, the path forward and how competitor data will be public soon.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Skye Bioscience's CEO Punit Dhillon discusses next generation CB1 inhibition for obesity, and flags how key data from competitor Novo coming this quarter could impact the class

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight